Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $242.50 short put and a strike $237.50 long put offers a potential 42.86% return on risk over the next 20 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $242.50 by expiration. The full premium credit of $1.50 would be kept by the premium seller. The risk of $3.50 would be incurred if the stock dropped below the $237.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 70.07 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline
Thu, 29 Jul 2021 19:00:00 +0000
Today at the Alzheimer's Association International Conference© (AAIC© 2021), Eli Lilly and Company (NYSE: LLY) presented two new exploratory analyses of data from the Phase 2 TRAILBLAZER-ALZ study. In the first, greater amyloid plaque changes following donanemab treatment was highly associated with less cognitive decline and participants with greater plaque clearance at 24 weeks of treatment showed less tau progression. In the second, Lilly shared data showing that treatment with donanemab drive
U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir
Thu, 29 Jul 2021 14:50:34 +0000
The U.S. health regulator expanded the emergency use authorization for Eli Lilly's COVID-19 drug baricitinib, saying it could now be used without taking Gilead's drug remdesivir along with it, Lilly said on Thursday. In November, the U.S. Food and Drug Administration (FDA) approved Lilly and Incyte's arthritis drug, baricitinib, in combination with remdesivir, to treat COVID-19 patients.
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
Thu, 29 Jul 2021 13:26:00 +0000
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today the U.S. Food and Drug Administration (FDA) has broadened the Emergency Use Authorization (EUA) for baricitinib to allow for treatment with or without remdesivir, whereas the EUA was previously restricted to use only in combination with remdesivir. The EUA now provides for the use of baricitinib for treatment of COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen,
Lilly, Kumquat Biosciences Team Up To Discover, Develop Immuno-Oncology Candidates
Thu, 29 Jul 2021 11:47:37 +0000
Loxo Oncology, a unit of Eli Lilly And Co (NYSE: LLY), and Kumquat Biosciences have announced an exclusive collaboration to discover, develop, and commercialize potential novel small molecules that stimulate tumor-specific immune responses. Through the multi-year collaboration, Kumquat will utilize its small molecule immuno-oncology (IO) platform to discover the candidates, and Lilly has the option to select a certain number of drug candidates for further development and commercialization worldw
Lilly signs deal with Kumquat Biosciences
Thu, 29 Jul 2021 11:28:18 +0000
Shares of Eli Lilly & Co. gained 0.6% in premarket trading on Thursday after the company announced a deal with Kumquat Biosciences to develop and commercialize small molecules that utilize Kumquat's immuno-oncology platform. The privately held Kumquat will receive $70 million, with up to $2 billion in available milestone payments. Lilly's stock is up 46.0% this year, while the broader S&P 500 has gained 17.1%.
Also on Market Tamer…
Follow Us on Facebook